There is no universally accepted instrument to use as a validated surrogate endpoint for
overall survival in phase 2 and phase 3 multimodal rectal cancer trials using …

Objective To investigate whether pretreatment MRI-based radiomics of locally advanced
rectal cancer (LARC) and/or the surrounding mesorectal compartment (MC) can predict …

Abstract Introduction The Neoadjuvant rectal (NAR) score is a new surrogate endpoint to be
used in clinical trials for early determination of treatment response to different preoperative …

The Cox Proportional Hazards regression is among the most widely used models in clinical
and epidemiological research for investigating the association between time-to-event …

Purpose To identify genes associated with treatment response and prognosis for locally
advanced rectal cancer (LARC) patients receiving neoadjuvant chemoradiotherapy (NCRT) …

Background Chemoradiation (CRT) or short-course radiotherapy (SCRT) are standard
treatments for locally advanced rectal cancer (LARC). We evaluated the efficacy/safety of …

Background The neoadjuvant rectal score (NAR) was developed as a surrogate endpoint for
overall survival in patients with rectal cancer after neoadjuvant treatment. We aimed to …

Introduction Neoadjuvant rectal (NAR) score may serve as a surrogate short‐term endpoint
for overall survival (OS) in clinical trials. This study aims to test the NAR score using a large …

Aim Neoadjuvant rectal (NAR) score is an early surrogate for longer‐term outcomes in rectal
cancer undergoing radiotherapy and resection. In an era of increasing organ preservation …

Abstracts Background Preclinical studies suggest that glucocorticoids (GCs) promote the
proliferation and development of colorectal cancer. Because GCs are broadly prescribed for …